<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445963</url>
  </required_header>
  <id_info>
    <org_study_id>S-15-19</org_study_id>
    <secondary_id>A-18716</secondary_id>
    <secondary_id>NMRC.2015.0003</secondary_id>
    <nct_id>NCT02445963</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)</brief_title>
  <official_title>A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, dose-escalating Phase 1 investigation of S. flexneri 2a
      InvaplexAR vaccine. A total of up to 40 subjects will receive one of four S. flexneri 2a
      InvaplexAR vaccine doses. The vaccine will be administered intranasally (without adjuvant).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine will be administered on Days 0,14, and 28. Volunteers (10 per group [8 minimum])
      will receive the same dose at each vaccination dependent upon group assignment. Groups will
      be divided according to the table below. An interval no less than 1 week will separate the
      third dose of a group from the first dose of the next group (receiving an increased
      InvaplexAR dose). Blood, stool, and saliva specimens will be collected at pre-specified
      intervals to examine systemic and mucosal vaccine antigen-specific immune responses. Ocular
      tear samples will be collected in groups C and D. Vaccine safety will be actively monitored
      during vaccination and for 28 days following the third vaccine dose. The decision to advance
      to the next dose level is based on the safety assessment (not immunogenicity). A dose level
      with no occurrence of stopping criteria in the 7 days following the last vaccine dose will
      prompt moving to the next higher level. All safety data will be summarized and reviewed with
      the research monitor prior to dose escalation. In addition, a report of all safety data will
      be provided to the sponsor's safety office for informational purposes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">May 13, 2016</completion_date>
  <primary_completion_date type="Actual">May 13, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Events</measure>
    <time_frame>166 days</time_frame>
    <description>Number of adverse events related to the vaccine for each arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Titers Against IgG and IgA Immunizing Antigens</measure>
    <time_frame>At screening and Days 0, 14, 28, 35, 42, and 56</time_frame>
    <description>Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers &lt; 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a &gt; 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer &gt;10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses</measure>
    <time_frame>56 Days</time_frame>
    <description>ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ASC response was defined as &gt; 10 ASCs above baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses</measure>
    <time_frame>56 Days</time_frame>
    <description>ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Shigellosis</condition>
  <condition>Bacillary Dysentery</condition>
  <arm_group>
    <arm_group_label>10 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects vaccinated on days 0, 14, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects vaccinated on days 0, 14, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects vaccinated on days 0, 14, 28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 subjects vaccinated on days 0, 14, 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Shigella flexneri 2a InvaplexAR</intervention_name>
    <description>The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
    <arm_group_label>10 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_label>250 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_label>50 μg S. flexneri 2a Invaplex</arm_group_label>
    <arm_group_label>500 μg S. flexneri 2a Invaplex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of
             enrollment.

          -  Completion and review of comprehension test (achieved &gt; 70% accuracy).

          -  Signed informed consent document.

          -  Available for the required follow-up period and scheduled clinic visits.

          -  Women: Negative pregnancy test with understanding (through informed consent process)
             to not become pregnant nor to breastfeed during the study or within 3 months following
             last vaccination

        Exclusion Criteria:

          -  Health problems (for example, chronic medical conditions such as psychiatric
             conditions, diabetes mellitus, hypertension, or any other conditions that might place
             the subjects at increased risk of adverse events)- study clinicians, in consultation
             with the PI, will use clinical judgment on a case-by-case basis to assess safety risks
             under this criterion. The PI will consult with the Research Monitor as appropriate.

          -  Clinically significant abnormalities on physical examination (chronic sinusitis or
             seasonal rhinitis) which compromise identification and interpretation of potential
             vaccine associated adverse effects.

          -  Use of immunosuppressive and/or immunomodulative drugs such as corticosteroids or
             chemotherapeutics that may influence antibody development.

          -  Immunosuppressive illnesses (including IgA deficiency defined by serum IgA below level
             of detection or &lt;7mg/dL).

          -  Participation in research involving another investigational product (defined as
             receipt of an investigational product or exposure to an invasive investigational
             device) 30 days before planned date of first vaccination or anytime throughout the
             duration of the study until the last study safety visit.

          -  Positive blood test for HBsAG, HCV, HIV-1/HIV-2.

          -  Clinically significant abnormalities on basic laboratory screening.

          -  Presence of significant unexplained laboratory abnormalities that in the opinion of
             the PI may potentially confound the analysis of the study results.

          -  Current smoker or smoker in past 1 year ('smoker' defined as daily cigarette, cigar,
             or pipe use for a period of at least 1 month).

        Research specific

          -  Structural abnormalities on sinus/nasal cavity examination.

          -  Rhinoplasty.

          -  Nasal polyps.

          -  Nasal ulcers.

          -  Deviated nasal septum. This question is being used to determine whether the volunteer
             has a clinically significant deviated septum that causes nasal obstruction (thereby
             causing difficulty breathing), interferes with normal sinus drainage, or obscures
             visualization of the posterior nasal cavity complicating examination and safety
             monitoring..

          -  Chronic sinusitis/rhinitis.

          -  Current or planned use of nasal topical corticosteroids and/or nasal spray medications
             in the 4 weeks prior to dosing or during the study vaccination period.

          -  Current or recent history (in the past 5 years) of reactive airway disease (asthma),
             chronic obstructive pulmonary disease, or chronic bronchitis.

          -  History of Bell's palsy.

          -  Chronic use (weekly or more often) of anti-diarrheal, anti-constipation, or antacid
             therapy (excluding use associated with spicy meals).

          -  Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day) on
             a regular basis; loose or liquid stools on other than an occasional basis.

          -  Personal or family history of inflammatory arthritis.

          -  Positive blood test for HLA-B27.

          -  History of allergy to any vaccine.

        Prior Exposure to Shigella

          -  Serum IgG titer ≥ 2500 to Shigella flexneri 2a LPS.

          -  History of microbiologically confirmed Shigella infection in the past 3 years.

          -  Received previous experimental Shigella vaccine or live Shigella challenge.

          -  Travel to countries with symptoms of travelers' diarrhea where Shigella or other
             enteric infections are endemic (most of the developing world) within the past 6 months
             prior to dosing.

          -  Occupation involving handling of Shigella bacteria currently, or in the past 3 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Duplessis, MD, MPH, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Enteric Diseases Department Naval Medical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Institute of Research, Clinical Trials Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <results_first_submitted>June 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2020</results_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="P2">
          <title>50 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="P3">
          <title>250 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="P4">
          <title>500 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change in employment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Symptoms post-vaccination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="B2">
          <title>50 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="B3">
          <title>250 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="B4">
          <title>500 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="22" upper_limit="28"/>
                    <measurement group_id="B2" value="34" lower_limit="26" upper_limit="42"/>
                    <measurement group_id="B3" value="28" lower_limit="27" upper_limit="31"/>
                    <measurement group_id="B4" value="28" lower_limit="24" upper_limit="36"/>
                    <measurement group_id="B5" value="28" lower_limit="24" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Related Adverse Events</title>
        <description>Number of adverse events related to the vaccine for each arm</description>
        <time_frame>166 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>10 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O2">
            <title>50 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O3">
            <title>250 μg S. Flexneri 2a Invaplex</title>
            <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O4">
            <title>500 μg S. Flexneri 2a Invaplex</title>
            <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Related Adverse Events</title>
          <description>Number of adverse events related to the vaccine for each arm</description>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Titers Against IgG and IgA Immunizing Antigens</title>
        <description>Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers &lt; 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a &gt; 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer &gt;10.</description>
        <time_frame>At screening and Days 0, 14, 28, 35, 42, and 56</time_frame>
        <population>Subjects who received at least 2 vaccine doses were included in the immunology analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>10 μg S. Flexneri 2a Invaplex</title>
            <description>8 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O2">
            <title>50 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O3">
            <title>250 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O4">
            <title>500 μg S. Flexneri 2a Invaplex</title>
            <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Titers Against IgG and IgA Immunizing Antigens</title>
          <description>Serum samples will be assayed for antibody titers against the immunizing antigens LPS, IpaB, IpaC, and S. flexneri 2a Invaplex at screening, and Days 0, 14, 28, 35, 42, and 56 for 36 subjects. Previously established high-titer specimens will be included on each plate to track day to day interassay variation. For each antigen, pre- and post-vaccination serum samples will be assayed side-by-side. The antibody titer assigned to each sample will represent the geometric mean of duplicate tests performed on 2 different days. Reciprocal endpoint titers &lt; 5 will be assigned a value of 2.5 for computational purposes. Seroconversion will be defined as a &gt; 4-fold increase in endpoint titer between pre-and post-vaccination samples AND a post-vaccination reciprocal titer &gt;10.</description>
          <population>Subjects who received at least 2 vaccine doses were included in the immunology analyses.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum IgG (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1345.4" lower_limit="805.0" upper_limit="2248.8"/>
                    <measurement group_id="O2" value="4703.2" lower_limit="2104.6" upper_limit="10510.2"/>
                    <measurement group_id="O3" value="5486.4" lower_limit="2199.0" upper_limit="13688.0"/>
                    <measurement group_id="O4" value="5571.5" lower_limit="2680.3" upper_limit="11581.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgA (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.4" lower_limit="108.4" upper_limit="620.7"/>
                    <measurement group_id="O2" value="800.0" lower_limit="330.7" upper_limit="1935.6"/>
                    <measurement group_id="O3" value="685.8" lower_limit="192.3" upper_limit="2445.5"/>
                    <measurement group_id="O4" value="606.3" lower_limit="259.3" upper_limit="1417.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgG (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1902.7" lower_limit="1138.4" upper_limit="3180.2"/>
                    <measurement group_id="O2" value="4703.2" lower_limit="2434.3" upper_limit="9086.5"/>
                    <measurement group_id="O3" value="4703.2" lower_limit="2939.8" upper_limit="7524.2"/>
                    <measurement group_id="O4" value="6400" lower_limit="3056.1" upper_limit="13402.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgA (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.4" lower_limit="108.4" upper_limit="620.7"/>
                    <measurement group_id="O2" value="635.0" lower_limit="330.6" upper_limit="1219.4"/>
                    <measurement group_id="O3" value="544.3" lower_limit="207.5" upper_limit="1428.2"/>
                    <measurement group_id="O4" value="527.8" lower_limit="233.3" upper_limit="1194.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgG (IpaB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.4" lower_limit="103.3" upper_limit="325.7"/>
                    <measurement group_id="O2" value="740.7" lower_limit="228.8" upper_limit="2397.8"/>
                    <measurement group_id="O3" value="342.9" lower_limit="86.4" upper_limit="1361.0"/>
                    <measurement group_id="O4" value="229.7" lower_limit="102.9" upper_limit="512.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgA (IpaB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="NA" upper_limit="NA">The data were not normally distributed</measurement>
                    <measurement group_id="O2" value="73.5" lower_limit="36.1" upper_limit="149.5"/>
                    <measurement group_id="O3" value="85.7" lower_limit="42.8" upper_limit="171.5"/>
                    <measurement group_id="O4" value="50.0" lower_limit="NA" upper_limit="NA">The data were not normally distributed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgG (IpaC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.4" lower_limit="171.2" upper_limit="660.7"/>
                    <measurement group_id="O2" value="2539.8" lower_limit="1049.8" upper_limit="6145.1"/>
                    <measurement group_id="O3" value="1728.1" lower_limit="353.8" upper_limit="8440.5"/>
                    <measurement group_id="O4" value="2599.2" lower_limit="1049.6" upper_limit="6436.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum IgA (IpaC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="38.1" upper_limit="131.4"/>
                    <measurement group_id="O2" value="317.5" lower_limit="72.0" upper_limit="1399.2"/>
                    <measurement group_id="O3" value="272.2" lower_limit="84.9" upper_limit="872.2"/>
                    <measurement group_id="O4" value="400.0" lower_limit="144.4" upper_limit="1108.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses</title>
        <description>ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ASC response was defined as &gt; 10 ASCs above baseline.</description>
        <time_frame>56 Days</time_frame>
        <population>Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm</population>
        <group_list>
          <group group_id="O1">
            <title>10 μg S. Flexneri 2a Invaplex</title>
            <description>8 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O2">
            <title>50 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O3">
            <title>250 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O4">
            <title>500 μg S. Flexneri 2a Invaplex</title>
            <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG and IgA Antigen-Specific Antibody Secreting Cell (ASC) Mucosal Responses</title>
          <description>ASC responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ASC responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ASC response was defined as &gt; 10 ASCs above baseline.</description>
          <population>Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm</population>
          <units>ASC per 10^6 PBMCs</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ASC IgG (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="5.0" upper_limit="12.0"/>
                    <measurement group_id="O4" value="9.0" lower_limit="4.0" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASC IgA (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="27.0" lower_limit="20.0" upper_limit="96.0"/>
                    <measurement group_id="O3" value="23.0" lower_limit="15.0" upper_limit="62.0"/>
                    <measurement group_id="O4" value="41.5" lower_limit="24.0" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASC IgG (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="0.0" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASC IgA (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="1.0" upper_limit="23.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="0.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses</title>
        <description>ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers.</description>
        <time_frame>56 Days</time_frame>
        <population>Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm</population>
        <group_list>
          <group group_id="O1">
            <title>10 μg S. Flexneri 2a Invaplex</title>
            <description>8 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O2">
            <title>50 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O3">
            <title>250 μg S. Flexneri 2a Invaplex</title>
            <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
          <group group_id="O4">
            <title>500 μg S. Flexneri 2a Invaplex</title>
            <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
          </group>
        </group_list>
        <measure>
          <title>IgG and IgA Antigen-Specific Antibody Lymphocyte Supernatant (ALS) Mucosal Responses</title>
          <description>ALS responses were assessed using isolated peripheral blood mononuclear cells (PBMCs). For each antigen, pre- and post-vaccination samples were tested on the same plates for total and vaccine-specific numbers. The ALS responses indirectly reflect intestinal immune responses through measurement of antigen-specific B-lymphocytes in systemic circulation before homing to gut effector sites. An ALS response was defined as a ≥ 4-fold increase over baseline ALS titers.</description>
          <population>Arm 1: One patient was lost to follow-up post dose 1 vaccination, overall participants is therefore 8 for this arm Arm 3: One patient withdrew from the study due to symptoms post dose 1 vaccination, overall participants is therefore 9 for this arm</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALS IgG (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.8" upper_limit="1.8"/>
                    <measurement group_id="O2" value="8.6" lower_limit="2.5" upper_limit="29.7"/>
                    <measurement group_id="O3" value="9.3" lower_limit="2.9" upper_limit="30.5"/>
                    <measurement group_id="O4" value="7.0" lower_limit="2.8" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALS IgA (Invaplex)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.7" upper_limit="2.4"/>
                    <measurement group_id="O2" value="8.6" lower_limit="2.4" upper_limit="30.5"/>
                    <measurement group_id="O3" value="3.7" lower_limit="1.3" upper_limit="10.9"/>
                    <measurement group_id="O4" value="4.3" lower_limit="1.7" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALS IgG (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.8" upper_limit="1.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="1.4" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="1.9" upper_limit="8.5"/>
                    <measurement group_id="O4" value="3.5" lower_limit="1.8" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALS IgA (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.5" upper_limit="6.7"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.2" upper_limit="3.4"/>
                    <measurement group_id="O4" value="2.1" lower_limit="1.2" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 8 months</time_frame>
      <desc>Vaccine-related (possibly, probably, definitely) surveyed signs and symptoms of all study subjects receiving at least one dose of investigational product was assessed through targeted physical exams, symptom surveys, and other adverse events (AE) monitoring. Subjects were observed in clinic for 30 minutes, 24 hours, and 7days post vaccination to review their symptom diaries and to report any AEs. All vaccine-related and unrelated (not related, unlikely) AEs were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>10 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="E2">
          <title>50 μg S. Flexneri 2a Invaplex</title>
          <description>9 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="E3">
          <title>250 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
        <group group_id="E4">
          <title>500 μg S. Flexneri 2a Invaplex</title>
          <description>10 subjects vaccinated on days 0, 14, 28
Shigella flexneri 2a InvaplexAR: The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Itchy Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tearing Eyes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Cramps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry Chapped Lips</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Loose Stools</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest Tightness (Unknown Etiology)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right Upper Lip Fever Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection (UTI)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST Elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>BUN Elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Low Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint Aches (Left Knee and Left Elbow)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Olecranon bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right Hip Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Right Knee Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Burning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Mucosal Hyperemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Stuffiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Post-Nasal Drip</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary Irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinus Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection (URI)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Systolic Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Duplessis, MD</name_or_title>
      <organization>Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center (CTC)</organization>
      <phone>301-319-9047</phone>
      <email>Christopher.a.duplessis.mil@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

